Mary P. Slack

Parklands Drive
Southport, QLD 4222, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

Correction: Méroc et al. Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine. Microorganisms 2023, 11, 1816.

Correction: Méroc et al. Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine. Microorganisms 2023, 11, 1816.

Journal: Microorganisms

Published: September 05, 2024

Pseudomonas aeruginosa bloodstream infections in children in Queensland, Australia, 2000-2019.

Pseudomonas aeruginosa bloodstream infections in children in Queensland, Australia, 2000-2019.

Journal: Journal of paediatrics and child health

Published: August 13, 2024

Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.

Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.

Journal: Vaccine

Published: October 26, 2023

A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom.

A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom.

Journal: Expert review of vaccines

Published: September 11, 2023

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine.

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine.

Journal: Microorganisms

Published: April 26, 2023

Long-Term effects of COVID-19: a review of current perspectives and mechanistic insights.

Long-Term effects of COVID-19: a review of current perspectives and mechanistic insights.

Journal: Critical reviews in microbiology

Published: April 19, 2023

Evaluation of the World Health Organization Global Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance Network's Laboratory External Quality Assessment Programme, 2014-2019.

Evaluation of the World Health Organization Global Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) Surveillance Network's Laboratory External Quality Assessment Programme, 2014-2019.

Journal: Journal of medical microbiology

Published: February 07, 2023

Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.

Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.

Journal: Vaccine

Published: January 18, 2023

Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection.

Effects of pneumococcal conjugate vaccines on reducing the risk of respiratory disease associated with coronavirus infection.

Journal: Pneumonia (Nathan Qld.)

Published: November 30, 2022

Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?

Pneumococcal Vaccination in Adults: What Can We Learn From Observational Studies That Evaluated PCV13 and PPV23 Effectiveness in the Same Population?

Journal: Archivos de bronconeumologia

Published: November 14, 2022

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.

Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: October 13, 2022

Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.

Public health and budgetary impact of 20-valent pneumococcal conjugate vaccine for adults in England.

Journal: Expert review of vaccines

Published: August 05, 2022

Showing 1-12 of 110

Last Updated: 09/26/2026